Advances in understanding and management of myeloproliferative neoplasms.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedAconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China.A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosisImmunomodulatory agents in myelofibrosis.Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasmsCurrent outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera.Chronic myeloproliferative neoplasms: a collaborative approach.mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia.Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosisThe effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Philadelphia-negative chronic myeloproliferative neoplasmsMyeloid neoplasms in the guise of nutritional deficiencyJAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Surgical treatment of a ventricular aneurysm in a patient with essential thrombocythemia complicated by acute myocardial infarction: A case reportThe JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia veraA nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation.Therapeutic approaches in myelofibrosis.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Emerging targeted therapies in myelofibrosis.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Emerging drugs for polycythemia vera.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
P2860
Q26738514-44B54B35-D441-4CA8-A186-454EFB2183AEQ27323049-940F23E6-18AB-42E3-814D-CE032D054671Q30244631-57D26A34-DFA3-4775-BEA0-A4899F382BBCQ31110460-40902D5C-3D06-44DD-AEBF-F7B82C281F37Q33393259-BE389A12-9A3E-4546-A34A-CD8EEB196A25Q33401615-987AF677-EC30-459E-8DB7-E277EDD54EEAQ33403735-766B48D0-605D-4C41-A9C6-1010CA7A6B56Q33405766-C7D56CBB-CBA3-4F8B-BD12-FEB04A20EF85Q33410346-FBBF32B7-AABE-4AB3-8492-A9ED3B33017DQ33432755-129B4298-1637-42A2-8966-BD6A8D7A3637Q33982315-97450736-5005-49A3-B434-8D1798B00B71Q34302770-5162ECFD-687A-446E-9AF8-380C6B41A088Q34477649-533DC206-20AC-42F7-880D-847F54F71589Q34549335-A38CA5E3-21BB-4532-8FD2-62FADC386893Q34575726-6B1334BF-755A-498C-AF98-5540C116C662Q34750599-F01BEFB8-7C1A-4D1E-A6D5-AB026BB3DECBQ35808066-153F2648-1B42-4600-B559-893D22A32A3AQ35856790-3F131E91-7AD7-4D46-AC5A-B5F1E804A708Q35944657-184AD8C1-FC86-42DC-AC2E-776E903F5939Q35975009-84A581B6-7243-445B-96FD-BF48FB21373FQ36003480-ACE1E9F0-2EC9-460A-AA30-BFD4BEC8086EQ36022526-EB0F7F48-2D6B-4404-AAA7-6DAD93E64476Q36091279-49F7B2C8-C680-4BB5-8EB7-4B5FAE28AE79Q36283143-812310B8-EE5F-4F9A-844D-2985A7F9F7A2Q36440032-FD20089D-0066-4F64-AF78-FB04FBD56695Q36612537-5C1E9F36-62D4-46CC-9B7A-5CB500908553Q36954379-0A760C41-93CF-429C-B001-443D42FF0091Q37163590-0049C9CD-1780-4221-BDE2-62E703F2D3E2Q37193961-7E2E3A9D-056F-416D-B3E6-F3B0C3193D97Q37310619-1F97F06E-E5AD-433C-9A0D-075435E18746Q37388591-B897012E-45C6-4EB6-B314-AA3631106568Q37406784-11E0A3D4-1254-45AF-BC31-B55CFCCD4AD7Q37682689-7019C555-0382-4D41-90AE-58BEF800A9F2Q37817621-1357BD2A-C42B-468B-91E5-CBB86F7B6937Q37860336-7FD68BEC-9A8B-43CF-8AB0-14869462AAFEQ38014534-5ADA6F11-1201-48C5-8CFE-5A64627976E3Q38025160-1BE0A9E1-A537-4C34-A03B-06E8FC6E9B47Q38100790-169EC3DA-5AD8-45C5-9FD9-1DC90DC7674AQ38130749-EF42E0BA-8E9C-4099-B6FE-925CB491F0A4Q38341625-997D6BA6-53A8-4289-8AFB-BC01E7E4926C
P2860
Advances in understanding and management of myeloproliferative neoplasms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Advances in understanding and management of myeloproliferative neoplasms.
@en
Advances in understanding and management of myeloproliferative neoplasms.
@nl
type
label
Advances in understanding and management of myeloproliferative neoplasms.
@en
Advances in understanding and management of myeloproliferative neoplasms.
@nl
prefLabel
Advances in understanding and management of myeloproliferative neoplasms.
@en
Advances in understanding and management of myeloproliferative neoplasms.
@nl
P356
P1433
P1476
Advances in understanding and management of myeloproliferative neoplasms.
@en
P2093
Alessandro M Vannucchi
Paola Guglielmelli
P304
P356
10.3322/CAAC.20009
P407
P577
2009-04-15T00:00:00Z